Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study.
Australia
cancer
naloxone
opioids
oxycodone
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
25
02
2020
accepted:
28
05
2020
pubmed:
15
9
2020
medline:
4
2
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Public subsidy of the oxycodone/naloxone controlled release (CR) combination in December 2011 expanded the overall market for oxycodone CR in the general public in Australia; we evaluate its impact in people with cancer. We used Repatriation Pharmaceutical Benefits dispensing data linked with the NSW Cancer Registry for Department of Veterans' Affairs (DVA) healthcare card holders 65 years and older residing in NSW between 2004 and 2013 to identify clients with cancer and their opioid dispensings. We used interrupted time series analysis to model changes in monthly rates of oxycodone CR tablets dispensed and initiations. We performed a retrospective cohort study to examine changes in client characteristics and opioid utilization over time by comparing clients initiating oxycodone CR before and after subsidy. The rate of oxycodone CR tablets dispensed/month increased by 20% from December 2011, due to uptake of the oxycodone/naloxone CR combination; monthly initiations increased immediately by 17%. Initiations of buprenorphine, fentanyl, and morphine declined from December 2011. DVA healthcare card holders were significantly more likely to initiate the 5 mg oxycodone CR formulation; more likely to use immediate release oxycodone in the 90 days following initiation; and less likely to use a weak opioid in the 90 days preceding oxycodone CR initiation following December 2011 than they were prior to that time. The public subsidy of the oxycodone/naloxone CR formulation expanded the overall oxycodone CR market for DVA healthcare card holders with cancer. Our findings highlight the need for updated guidelines around risk management for opioid treatment in patients with cancer.
Substances chimiques
Analgesics, Opioid
0
Delayed-Action Preparations
0
Drug Combinations
0
oxycodone naloxone combination
0
Naloxone
36B82AMQ7N
Oxycodone
CD35PMG570
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-78Subventions
Organisme : National Health and Medical Research Council
ID : 1060407
Informations de copyright
© 2020 The Commonwealth of Australia. Asia-Pacific Journal of Clinical Oncology © 2020 John Wiley & Sons Australia, Ltd.
Références
Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78(5):1159-1166.
Fischer B, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf. 2011;20(12):1269-1277.
Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop WCN. Estimating the health care burden of prescription opioid abuse in five European countries. Clinicoecon Outcomes Res. 2015;7:477-488.
Shipton EE, Shipton AJ, Williman JA, Shipton EA. Deaths from opioid overdosing: implications of coroners’ inquest reports 2008-2012 and annual rise in opioid prescription rates: a population-based cohort study. Pain Ther. 2017;6(2):203-215.
Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths-United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA. 2016;315(15):1624-1645.
Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain-an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592.
Lovell M, Luckett T, Boyle F, et al. Adaptation of international guidelines on assessment and management of cancer pain for the Australian context. Asia Pac J Clin Oncol. 2015;11(2):170-177.
Royal Australian College of General Practitioners. Prescribing Drugs of Dependence in General Practice, Part C2: The Role of Opioids in Pain Management. Melbourne; 2017.
Nicholas R, Lee N, Roche A. A Review of the Literature Supporting the Development of Australia's National Pharmaceutical Drug Misuse Strategy. Adelaide: National Centre for Education and Training on Addiction (NCETA), Flinders University; 2011.
Dalal S, Bruera E. Pain management for patients with advanced cancer in the opioid epidemic era. Am Soc Clin Oncol Educ Book. 2019;39:24-35.
Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.
Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol. 2016;82(1):255-267.
Schaffer AL, Karanges EA, Buckley NA, et al. Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: an Australian population-based study. Pharmacoepidemiol Drug Saf. 2019;28(1):97-105.
Pearson S-A, Schaffer A. The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians. BMJ Open. 2014;4(5):e004099.
Australian Government Department of Veterans' Affairs. Factsheet HSV92 - Repatriation Pharmaceutical Benefits Scheme. 2019. Available fromhttps://www.dva.gov.au/factsheet-hsv92-repatriation-pharmaceutical-benefits-scheme. Accessed December 12, 2019.
Cancer Institute NSW. NSW Cancer Registry. 2018. Available from https://www.cancer.nsw.gov.au/data-research/data-held-by-cinsw/nsw-cancer-registry. Accessed December 12, 2019.
Lalic S, Ilomaki J, Bell JS, Korhonen MJ, Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol. 2019;85(1):202-215.
Gisev N, Pearson S-A, Blanch B, et al. Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. Br J Clin Pharmacol. 2016;82(4):1123-1133.
Review IfCaE. Abuse-Deterrent Opioids: Final Evidence Report. 2017. Available from https://icer-review.org/material/adf-final-report/. Accessed February 7, 2020.
Turk DC, Dansie EJ, Wilson HD, Moskovitz B, Kim M. Physicians' beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients. Pain Med. 2014;15(4):625-636.
The Royal Australasian College of Physicians. Prescription Opioid Policy: Improving Management of Chronic Non-Malignant Pain and Prevention of Problems Associated with Prescription Opioid Use. Sydney: RACP; 2009.